Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXPOTCMKTS:BETRFNASDAQ:KPRXOTCMKTS:VGLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$0.40+0.7%$0.47$0.30▼$3.33$9.00M-1.36155,780 shs82,898 shsBETRFBetterLife Pharma$0.07+2.9%$0.07$0.05▼$0.15$9.06M1.4714,928 shs1,200 shsKPRXKiora Pharmaceuticals$3.20$3.05$2.51▼$5.55$9.60M-0.5331,173 shs9,261 shsVGLSVG Life Sciences$0.00$0.00$0.00▼$0.00$2.11M1.817.51 million shs1.00 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals0.00%+9.35%-4.55%-53.58%-80.07%BETRFBetterLife Pharma0.00%+9.38%+4.79%-38.49%-2.64%KPRXKiora Pharmaceuticals0.00%+14.70%+5.96%-16.45%-29.70%VGLSVG Life Sciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals2.9394 of 5 stars3.55.00.00.03.31.70.0BETRFBetterLife Pharma0.2391 of 5 stars0.03.00.00.00.01.70.0KPRXKiora Pharmaceuticals4.1561 of 5 stars3.85.00.00.04.41.71.9VGLSVG Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 3.00Buy$12.002,865.89% UpsideBETRFBetterLife Pharma 0.00N/AN/AN/AKPRXKiora Pharmaceuticals 3.50Strong Buy$10.00212.50% UpsideVGLSVG Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VGLS, KPRX, ACXP, and BETRF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025KPRXKiora PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/19/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.34 per shareN/ABETRFBetterLife PharmaN/AN/AN/AN/A($0.05) per shareN/AKPRXKiora Pharmaceuticals$16M0.60N/AN/A$7.14 per share0.45VGLSVG Life SciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.58M-$0.87N/AN/AN/AN/A-392.36%-223.78%5/13/2025 (Estimated)BETRFBetterLife Pharma-$2.14M-$0.03N/A∞N/AN/AN/A-999.57%5/27/2025 (Estimated)KPRXKiora Pharmaceuticals-$12.51M$1.043.08N/AN/AN/A21.32%16.39%5/9/2025 (Estimated)VGLSVG Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/ALatest VGLS, KPRX, ACXP, and BETRF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ACXPAcurx Pharmaceuticals-$0.14N/AN/AN/AN/AN/A5/9/2025Q1 2025KPRXKiora Pharmaceuticals-$0.77N/AN/AN/A$0.75 millionN/A3/25/2025Q4 2024KPRXKiora Pharmaceuticals-$0.64-$1.04-$0.40-$1.04$0.75 million$0.75 million3/17/2025Q4 2024ACXPAcurx Pharmaceuticals-$0.18-$0.16+$0.02-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/ABETRFBetterLife PharmaN/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/AVGLSVG Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A1.801.80BETRFBetterLife PharmaN/A0.050.05KPRXKiora PharmaceuticalsN/A8.978.97VGLSVG Life SciencesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%BETRFBetterLife Pharma0.01%KPRXKiora Pharmaceuticals76.97%VGLSVG Life SciencesN/AInsider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals29.60%BETRFBetterLife Pharma34.77%KPRXKiora Pharmaceuticals0.94%VGLSVG Life SciencesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals322.40 million11.99 millionOptionableBETRFBetterLife Pharma7129.46 million84.45 millionNot OptionableKPRXKiora Pharmaceuticals103.00 million2.97 millionNot OptionableVGLSVG Life Sciences121.10 billionN/ANot OptionableVGLS, KPRX, ACXP, and BETRF HeadlinesRecent News About These CompaniesCamfil USA Unveils Absolute® VG: Advanced V-Bank HEPA Filters with Gasket and Gel SealsOctober 31, 2024 | markets.businessinsider.comVG Life Sciences Inc.September 14, 2024 | barrons.comVG Life Sciences, Inc. Increases Authorized SharesAugust 17, 2024 | br.advfn.comVG Life Sciences Inc. Moves to Restore Financial Accountability & Completes Prior Year Audits, Plans to File Form 10August 17, 2024 | br.advfn.comVG Life Sciences Inc. (VGLS)March 1, 2024 | finance.yahoo.comVG Life Sciences Stock (OTC:VGLS), Insider Trading ActivityFebruary 27, 2024 | benzinga.comEmerging from a Recent Pullback, Life Sciences Has a PulseJanuary 18, 2024 | globest.comVG Life Sciences Inc VGLSNovember 16, 2023 | morningstar.comReport warns of 'oversupply' of life sciences real estateSeptember 17, 2023 | bizjournals.comVGLS VG Life Sciences Inc.February 16, 2023 | seekingalpha.comThe best Life is Strange game is on PlayStation Plus right now – and it’s not what you thinkJanuary 27, 2023 | vg247.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVGLS, KPRX, ACXP, and BETRF Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$0.40 +0.00 (+0.72%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$0.40 0.00 (-0.64%) As of 04/25/2025 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.BetterLife Pharma OTCMKTS:BETRF$0.07 +0.00 (+2.94%) As of 04/25/2025 09:30 AM EasternBetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.Kiora Pharmaceuticals NASDAQ:KPRX$3.20 0.00 (0.00%) Closing price 04/25/2025 03:58 PM EasternExtended Trading$3.24 +0.04 (+1.41%) As of 04/25/2025 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.VG Life Sciences OTCMKTS:VGLS$0.0001 0.00 (0.00%) As of 04/25/2025 11:57 AM EasternVG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
